Difference between revisions of "About-cancer/treatment/drugs/melanoma"
(Created page with "== Drugs Approved for Melanoma == This page lists cancer drugs approved by the Food and Drug Administration (FDA) for melanoma. The list includes generic names and brand name...") |
(Marked this version for translation) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | == Drugs Approved for Melanoma == | + | <languages/> |
| + | <translate> | ||
| + | == Drugs Approved for Melanoma == <!--T:1--> | ||
| + | <!--T:2--> | ||
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for melanoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in melanoma that are not listed here. | This page lists cancer drugs approved by the Food and Drug Administration (FDA) for melanoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in melanoma that are not listed here. | ||
| + | <!--T:3--> | ||
'''Drugs Approved for Melanoma''' | '''Drugs Approved for Melanoma''' | ||
| + | <!--T:4--> | ||
Aldesleukin | Aldesleukin | ||
| + | <!--T:5--> | ||
Binimetinib | Binimetinib | ||
| + | <!--T:6--> | ||
Braftovi (Encorafenib) | Braftovi (Encorafenib) | ||
| + | <!--T:7--> | ||
Cobimetinib | Cobimetinib | ||
| + | <!--T:8--> | ||
Cotellic (Cobimetinib) | Cotellic (Cobimetinib) | ||
| + | <!--T:9--> | ||
Dabrafenib Mesylate | Dabrafenib Mesylate | ||
| + | <!--T:10--> | ||
Dacarbazine | Dacarbazine | ||
| + | <!--T:11--> | ||
Encorafenib | Encorafenib | ||
| + | <!--T:12--> | ||
IL-2 (Aldesleukin) | IL-2 (Aldesleukin) | ||
| + | <!--T:13--> | ||
Imlygic (Talimogene Laherparepvec) | Imlygic (Talimogene Laherparepvec) | ||
| + | <!--T:14--> | ||
Interleukin-2 (Aldesleukin) | Interleukin-2 (Aldesleukin) | ||
| + | <!--T:15--> | ||
Intron A (Recombinant Interferon Alfa-2b) | Intron A (Recombinant Interferon Alfa-2b) | ||
| + | <!--T:16--> | ||
Ipilimumab | Ipilimumab | ||
| + | <!--T:17--> | ||
Keytruda (Pembrolizumab) | Keytruda (Pembrolizumab) | ||
| + | <!--T:18--> | ||
Mekinist (Trametinib) | Mekinist (Trametinib) | ||
| + | <!--T:19--> | ||
Mektovi (Binimetinib) | Mektovi (Binimetinib) | ||
| + | <!--T:20--> | ||
Nivolumab | Nivolumab | ||
| + | <!--T:21--> | ||
Opdivo (Nivolumab) | Opdivo (Nivolumab) | ||
| + | <!--T:22--> | ||
Peginterferon Alfa-2b | Peginterferon Alfa-2b | ||
| + | <!--T:23--> | ||
PEG-Intron (Peginterferon Alfa-2b) | PEG-Intron (Peginterferon Alfa-2b) | ||
| + | <!--T:24--> | ||
Pembrolizumab | Pembrolizumab | ||
| + | <!--T:25--> | ||
Proleukin (Aldesleukin) | Proleukin (Aldesleukin) | ||
| + | <!--T:26--> | ||
Recombinant Interferon Alfa-2b | Recombinant Interferon Alfa-2b | ||
| + | <!--T:27--> | ||
Sylatron (Peginterferon Alfa-2b) | Sylatron (Peginterferon Alfa-2b) | ||
| + | <!--T:28--> | ||
Tafinlar (Dabrafenib Mesylate) | Tafinlar (Dabrafenib Mesylate) | ||
| + | <!--T:29--> | ||
Talimogene Laherparepvec | Talimogene Laherparepvec | ||
| + | <!--T:30--> | ||
Trametinib | Trametinib | ||
| + | <!--T:31--> | ||
Vemurafenib | Vemurafenib | ||
| + | <!--T:32--> | ||
Yervoy (Ipilimumab) | Yervoy (Ipilimumab) | ||
| + | <!--T:33--> | ||
Zelboraf (Vemurafenib) | Zelboraf (Vemurafenib) | ||
| + | </translate> | ||
Latest revision as of 21:34, 29 October 2019
Drugs Approved for Melanoma
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for melanoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in melanoma that are not listed here.
Drugs Approved for Melanoma
Aldesleukin
Binimetinib
Braftovi (Encorafenib)
Cobimetinib
Cotellic (Cobimetinib)
Dabrafenib Mesylate
Dacarbazine
Encorafenib
IL-2 (Aldesleukin)
Imlygic (Talimogene Laherparepvec)
Interleukin-2 (Aldesleukin)
Intron A (Recombinant Interferon Alfa-2b)
Ipilimumab
Keytruda (Pembrolizumab)
Mekinist (Trametinib)
Mektovi (Binimetinib)
Nivolumab
Opdivo (Nivolumab)
Peginterferon Alfa-2b
PEG-Intron (Peginterferon Alfa-2b)
Pembrolizumab
Proleukin (Aldesleukin)
Recombinant Interferon Alfa-2b
Sylatron (Peginterferon Alfa-2b)
Tafinlar (Dabrafenib Mesylate)
Talimogene Laherparepvec
Trametinib
Vemurafenib
Yervoy (Ipilimumab)
Zelboraf (Vemurafenib)
